Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 16/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ABL2 | P42684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097153 | 0.96 | ADORA2B (0.40) | ADORA2BADORA2AADORA3DNMT3A | |
| SCHEMBL21096789 | 0.86 | ADORA2B (0.35) | ADORA2BADORA2AADORA3 | |
| SCHEMBL21096681 | 0.84 | ACVR1 (0.35) | ADORA2BADORA2AADORA3 | |
| SCHEMBL21096555 | 0.83 | CYP1A2 (0.36) | ADORA2BADORA2A | |
| SCHEMBL21097151 | 0.81 | CDK7 (0.38) | ADORA2BADORA2A | |
| SCHEMBL21096684 | 0.79 | PIK3CA (0.39) | ADORA2BADORA2AADORA3SRCABL1 | |
| SCHEMBL21096807 | 0.78 | PIK3CA (0.40) | ADORA2BADORA2AADORA3SRCABL1 | |
| SCHEMBL16205377 | 0.72 | SRC (0.44) | SRCABL1EGFRABL2 | |
| SCHEMBL21096553 | 0.71 | GAA (0.39) | ADORA2BADORA2A | |
| SCHEMBL19114698 | 0.70 | SRC (0.44) | SRCABL1EGFRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | ADORA2B 4163/4885ADORA2A 4258/4885ADORA3 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.